<DOC>
	<DOCNO>NCT01352585</DOCNO>
	<brief_summary>This study hypothesis-generating explore impact JAK2 ( V617F ) mutation status treatment response anagrelide hydrochloride</brief_summary>
	<brief_title>Exploratory Multi-centre Trial In Patients With ET Treated With XAGRIDÂ®</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Anagrelide</mesh_term>
	<criteria>1 . Patients must able understand willing participate study , provide personally dated sign write informed consent form . 2 . Patients must confirm diagnosis ET accord World health Organisation 's criterion . 3 . ET patient uncontrolled , Investigator 's opinion , firstline ( previous ) cytoreductive treatment efficacy tolerance reason . 4 . Patients either commenced treatment anagrelide hydrochloride last 7 day decision document commence treatment anagrelide hydrochloride 1 . Patients treatment anagrelide hydrochloride contraindicate , accord current XAGRID SmPC . 2 . Known suspected intolerance hypersensitivity product , closely related compound , state ingredient . 3 . Patients participate interventional research study . 4 . Patients combination therapy intention treat cytoreductive agent e.g. , hydroxyurea , interferon . Patients however use aspirin antiaggregatory product Investigator 's discretion .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>